Lopina, NataliiaDmytrenko, IrynaHamov, DmytroLopin, DmytroDyagil, Iryna2019-12-012019-12-012019Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic Imatinib-induced liver injury / N. Lopina, I. Dmytrenko, D. Hamov, D. Lopin, I. Dyagil // Cureus. ‒ 2019. ‒ Vol. 11, N 4. ‒ e4411. ‒ DOI: 10.7759/cureus.4411.https://repo.knmu.edu.ua/handle/123456789/25123The tyrosine kinase inhibitor (TKI) imatinib in rare cases can cause acute toxic hepatitis, hepatic failure, and death. Currently, the choice of further chronic myeloid leukemia (CML) therapy in patients after acute hepatotoxicity is still a difficult question, which requires a complex individual approach based on the clinical guidelines of adverse event management. Data about the further follow-up strategy approach in patients with CML after acute toxic imatinib-induced liver injury are of concern, and at times controversial. In addition, one of the questions is about the necessity and safety of the imatinib therapy resumption after acute hepatotoxicity. In some publications, imatinib resumption without the recurrence of hepatotoxicity has been discussed; in others, imatinib resumption with the recurrence of imatinib hepatotoxicity has been mentioned.enacute toxic hepatitisacute liver failurechronic myeloid leukemiachronic myeloid leukemia second-line therapytyrosine kinase inhibitorsimatinibdruginduced liver diseaseArticle